24/7 Wall Street
15 Jul 2026, 11:45 UTC · 1h ago
AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
15 Jul 2026, 11:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
AbbVie raised its full-year adjusted EPS guidance to a range of $14.08 to $14.28 following strong Q1 2026 results. — Upward guidance revisions typically drive positive price action as they signal stronger-than-expected fundamental growth.
+0.60Baxter International reported a FY2025 net loss of $900 million and effectively eliminated its dividend payout. — The combination of substantial net losses and the removal of a dividend makes a stock unattractive to income investors and indicates severe fundamental distress.
-0.60AbbVie's Skyrizi and Rinvoq drugs grew 31% and 23% respectively in Q1 2026, offsetting biosimilar losses for Humira. — Proven ability to replace legacy revenue with new growth engines reduces the long-term risk of the company's product pipeline.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
Baxter's 2026 adjusted EPS guidance of $1.85 to $2.05 represents a step-down from the previous $2.27. — A downward revision in earnings expectations suggests continuing operational headwinds and a slowing recovery.
-0.30Both AbbVie and Baxter recently exhibited a 'golden cross' technical signal, though AbbVie's is widening while Baxter's is narrow and on a declining 200-day average. — While golden crosses are bullish momentum indicators, the disparity in quality suggests the signal is much more reliable for AbbVie than Baxter.
+0.10Which stocks this story touches
The company reported strong growth in Skyrizi and Rinvoq, raised full-year guidance, and maintains a growing dividend.
The company eliminated its dividend, posted significant net losses for FY2025, and is described as a speculative turnaround play.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
50m ago
